El Qué, Cómo y Cuándo de los Test de Detección de COVID-19
DOI:
https://doi.org/10.66737/ier.zub.302Keywords:
Detection test, PCR, antigen test, serological test, detection windowAbstract
In recent months we have experienced a global pandemic of dimensions that we could not have imagined a few years ago. We have learned new terms, new scientific techniques, how to interpret epidemiological data and, above all, how to appreciate the fundamental role of science. One of the main keys in this pandemic has been detection tests to find out if a person
is infected and to be able to trace cases. In this article, a description of the main tests is given, including information on what information they provide, the window of detection and the pros and cons. These techniques can be used not only for this disease, but also for many other cases and for various applications. This article is intended to shed light on the what, how and when of infectious disease screening tests in order to better understand these biochemical techniques.
Downloads
References
Asín, A., García-Martín, F., Busto, JH., Avenoza, A., Peregrina, JM., Corzana, F. (2022). Structure-based Design of Anti-cancer Vaccines: The Significance of Antigen Presentation to Boost the Immune Response. Current Medicinal chemistry, 29(7), 1258-1270.
Bermejo, IA., Navo, CD., Castro-López, J., et al., (2020) Synthesis, conformational analysis and: In vivo assays of an anti-cancer vaccine that features an unnatural antigen based on an sp2-iminosugar fragment. Chemical Science, 11, 3996–4006.
Bivins, A., North, D., Ahmad, A., et al., (2020) Wastewater-Based Epidemiology:
Global Collaborative to Maximize Contributions in the Fight against COVID-19. Environmental Science and Technology, 54, 7754–7757.
Coelho, H., Matsushita, T., Artigas, G,, (…), García-Martín, F., Marcelo, F. (2015) The Quest for Anticancer Vaccines: Deciphering the Fine-Epitope Specificity of Cancer-Related Monoclonal Antibodies by Combining Microarray Screening and Saturation Transfer Difference NMR. Journal of the American Chemical Society, 137, 12438–12441.
Corman, V.M., Landt, O., Kaiser, M., et al., (2020). Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance, 25, 2000045.
Guillen-Poza, PA., Sánchez-Fernández, EM., Artigas, G., (…), García-Martín, F. (2020). Amplified Detection of Breast Cancer Autoantibodies Using MUC1-Based Tn Antigen Mimics. Journal of Medicinal Chemistry, 63, 8524–8533.
Lee, CYP., Lin, RTP., Renia, L., et al., (2020). Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control. Frontiers in Immunology, 11, 879.
Martini, M., Gazzaniga, V., Bragazzi, NL., et al., (2019). The Spanish Influenza
Pandemic: A lesson from history 100 years after 1918. Journal of Preventive Medicine and Hygiene, 60, E64–E67.
Mullis, K.B. (1993). Nobel Lecture: The Polymerase Chain Reaction, https://www.nobelprize.org/prizes/chemistry/1993/mullis/lecture/ (accessed May 11, 2021).
Organización Mundial de la Salud (2021). Nuevo coronavirus 2019. https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019 (accessed Nov 24, 2021).
Peeling, R.W., Olliaro, P.L,, Boeras, D.I., et al., (2021). Scaling up COVID-19 rapid antigen tests: promises and challenges. The Lancet Infectious Diseases, 21, E290–E295.
Randazzo, W., Truchado, P., Cuevas-Ferrando, E., et al., (2020). SARS-CoV-2 RNA in wastewater anticipated COVID-19 occurrence in a low prevalence area. Water Research, 181, 115942.
Saiki, R., Gelfand, D., Stoffel, S., et al., (1988). Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science, 239, 487–491.
Somovilla, VJ., Bermejo, IA., Albuquerque, IS., et al., (2017). The Use of Fluoroproline in MUC1 Antigen Enables Efficient Detection of Antibodies in Patients with Prostate Cancer. Journal of the American Chemical Society, 139, 18255–18261.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Fayna María García Martín (Autor/a)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Los autores que publican en Zubía conservan los derechos de autor de sus trabajos y autorizan a la revista la primera publicación de los mismos.
Los artículos se publican bajo la licencia Creative Commons Atribución–No Comercial–Compartir Igual (CC BY-NC-SA), que permite su uso, distribución y reproducción en cualquier medio, siempre que se cite adecuadamente la autoría original, no se realice un uso comercial y se mantenga la misma licencia.
